.jetcityimage/iStock Editorial using Getty Images Morgan Stanley has selected Eli Lilly (NYSE: LLY) as its own top biopharma selection for 2025 and also measured yet another 9 titles in the space as obese. The assets bank stated in a details that it remains to strongly believe “diabesity is set to become.